Aston University

Myricx Bio Appoints Dr Chris Martin, Biotech Entrepreneur and ADC Pioneer, as Chairman of its Board of Directors

Retrieved on: 
Wednesday, November 15, 2023
Aston, Engineering physics, NYSE, NMT, Francis Crick Institute, AstraZeneca, Spacecraft, Therapy, Biology, ADC, CSO, Patient, Sofinnova, MedImmune, Chemical engineering, Chris, Aston University, MBA, Drug discovery, University, Cancer, Imperial College London, IMD, Institution of Chemical Engineers, Knowledge, New York Stock Exchange, Fine chemical, Pharmaceutical industry

Dr Martin is a renowned biotech company founder, director and entrepreneur, and a pioneer and leader in the ADC space.

Key Points: 
  • Dr Martin is a renowned biotech company founder, director and entrepreneur, and a pioneer and leader in the ADC space.
  • Dr Martin was instrumental in co-founding ADC Therapeutics (NYSE: ADCT) in Jan 2012 and served as its CEO since inception until May 2022.
  • Alongside his role as Chairman of Myricx, he is also Chairman of the Board of Tokamak Energy Ltd, and Tagworks Pharmaceuticals BV, and a Director on the Board of Osivax SAS.
  • Dr Robin Carr, Myricx CEO and Board Director, said, “We are thrilled that Chris has joined our Board and taken on the role of Chairman.

How new 'consumer duty' rules for financial products could reduce debt-related stress

Retrieved on: 
Friday, July 28, 2023
Aston, Review, Association, Pressure, Employment, Housing, Life, Face, Financial Conduct Authority, Aston University, Feedback, Pension, St. Louis Fed Financial Stress Index, Woman, Research, Birmingham City Council, Grief, Man, City, Income, Gambling, FCA, Bank, Life insurance

New “consumer duty” rules introduced by the Financial Conduct Authority (FCA) aim to set clear standards for the protection of financial consumers.

Key Points: 
  • New “consumer duty” rules introduced by the Financial Conduct Authority (FCA) aim to set clear standards for the protection of financial consumers.
  • Amid a cost of living crisis, the UK regulator’s new rules should hopefully address the increasing recognition by consumer groups that people cannot always solve the financial problems they face.
  • A major part of this responsiveness will involve listening to and understanding the real-life experiences of financial consumers.
  • Research shows the ways in which financial service companies could improve how they deal with their consumers.

Preventing problems from escalating

    • Preventing negative escalations should be a priority when consumers in tough financial situations are unable to pay their bills and debt starts to mount.
    • They also need appropriate support to help overcome the stigma of experiencing financial problems.
    • The government’s “breathing space” scheme gives people experiencing debt problems time to receive advice and find a solution without penalties.

Listening to feedback

    • Disparities in income and wealth between men and women, for example, relate to different work and employment experiences and opportunities.
    • Financial products such as pensions and investment accounts often appear to be gender neutral, but do not actually align with different life experiences.
    • This is one of the reasons why it is important for consumers to give feedback directly to the firms they deal with, so they can create different products.
    • The consumer duty rules should help to facilitate this kind of feedback, resulting in financial products with a more diverse appeal and better outcomes.

Three COVID-era lessons to help support employee wellbeing in times of crisis

Retrieved on: 
Monday, July 24, 2023
People, Aston, Heart, Uncertainty, Communication, Optimism, University, Moses Austin, Senior, Friends, Aston University, Social support, Leadership, Survival, California State University, Mental health, Hope, Research, COVID, Mental, Work, Family, Safety, Tourism, Nursing, Management

But organisations can learn a lot from how they acted during COVID to help protect employee wellbeing.

Key Points: 
  • But organisations can learn a lot from how they acted during COVID to help protect employee wellbeing.
  • Companies may even be able to support employee wellbeing better than they did during COVID.
  • In a related study, we showed how social support can help you to effectively adapt to changing circumstances, which also protects your wellbeing.
  • We found there are three key ways to protect employee wellbeing during such times.

1. Build trust

    • They can demonstrate they are competent and capable in making good decisions during critical times.
    • If things change and management has to make difficult decisions, they should communicate openly about this and consult with employees.
    • Line managers also have a role in reinforcing and helping to facilitate trust.

2. Harness the protective effects of social support

    • Employees should also be able to access more informal support by confiding in their line manager.
    • As our research shows, reaching out to family and friends is also an important source of support.

3. Adapt to thrive rather than cope to survive

    • This could include regular discussions or personal activities that help people to reflect on and interpret what has happened to them that day or week.
    • This can help maintain a sense of meaning and purpose during times of uncertainty and change.
    • They could also be discussed during weekly team meetings to encourage employees to set small incremental goals or use coping techniques more often.

Patient Experience Journal Releases The Newest Volume: Volume 10, Issue 1

Retrieved on: 
Monday, May 1, 2023
Aston, Pediatric emergency medicine, Cleveland Clinic, University of Alabama, University, Aston University, BC Cancer Agency, University of Ottawa, University of Pennsylvania, Research, Montana State University, Safety (gridiron football position), Thought, University of Exeter, Sandwell and West Birmingham Hospitals NHS Trust, Sunnybrook Health Sciences Centre, Nursing, Book, Island Health

NASHVILLE, Tenn., May 1, 2023 /PRNewswire-PRWeb/ -- The Beryl Institute announces the publication of Volume 10, Issue 1 of Patient Experience Journal (PXJ), an international, open access, peer-reviewed journal focused on research and proven practices related to understanding and improving the patient experience. Read in over 220 countries and territories, PXJ articles have been downloaded over 1,100,000 times and reflect the journal's commitment to disseminating rigorous knowledge and expanding the global conversation on evidence and innovation in patient and human experience.

Key Points: 
  • It has become a place for conversation.
  • It has served as a conduit for expanding excellence in practice," said Jason Wolf, Founding Editor of PXJ and President & CEO of The Beryl Institute.
  • It is a shared sense of purpose and of possibility.
  • And we are forever grateful to our authors, reviewers and readers for being true champions for transforming the human experience."

Osivax Appoints Dr. Chris Martin, Renowned Biotech Entrepreneur, to its Board of Directors

Retrieved on: 
Thursday, February 23, 2023
Health, Infectious Diseases, Other Health, Research, Science, Pharmaceutical, Biotechnology, Aston, Chemical engineering, Knowledge, Therapy, University, MBA, Spacecraft, MedImmune, Entrepreneurship, Growth, International Institute for Management Development, AstraZeneca, Engineering physics, Antibody-drug conjugate, Aston University, Vaccine, Jim May (chemical engineer), Pharmaceutical industry

Osivax , a biopharmaceutical company developing vaccines to provide broad-spectrum protection against highly mutating infectious viruses and diseases, announced today the appointment of Dr. Chris Martin to its Board of Directors.

Key Points: 
  • Osivax , a biopharmaceutical company developing vaccines to provide broad-spectrum protection against highly mutating infectious viruses and diseases, announced today the appointment of Dr. Chris Martin to its Board of Directors.
  • Dr. Martin brings with him over 20 years of experience in the pharmaceutical and biotech sector.
  • He is an accomplished company founder and director who has successfully brought technology from the lab to regulatory approval and global markets.
  • “We are deeply saddened by the loss of Dr. Mike Watson, who served on our Board of Directors with distinction.

Disrupting the Disruptors: Proptech Platform Homemove Secures $400,000 in Funding

Retrieved on: 
Tuesday, January 17, 2023
Aston, Watsons, University of East Anglia, Jaguar Land Rover, Trust, Eilidh, Estate agent, East Anglia, Partnership, National Association, Growth, Aston University, Fuel, Bachelor, Legal & General, Friction, Research, Sale, CRMS, Commercial, Real estate, Management, NORWICH

NORWICH, England, Jan. 17, 2023 /PRNewswire/ -- Homemove , a tech platform connecting sellers, buyers and renters with vetted, trusted and established home moving services, has raised $400,000 in pre-seed funding to aid rapid growth.

Key Points: 
  • NORWICH, England, Jan. 17, 2023 /PRNewswire/ -- Homemove , a tech platform connecting sellers, buyers and renters with vetted, trusted and established home moving services, has raised $400,000 in pre-seed funding to aid rapid growth.
  • In an effort to challenge the so-called 'disruptors', Homemove will be promoting the best local and independent service providers who prioritise their clients' best interests.
  • Louis O'Connell-Bristow , Homemove co-founder & CEO, said: "My vision is to significantly improve the home moving process and this funding round is a major step towards achieving that goal.
  • James Freestone , Homemove co-founder & COO, said: "At Homemove, we are not just building a brand, we are building a legacy of trust and excellence.

Cambrian BioPharma Unveils New Pipeline Company - Isterian Biotech

Retrieved on: 
Thursday, January 12, 2023
Aston, Cell, Ageing, Tissue, Longevity, ECM, Extracellular matrix, Lung, Protein, Aston University, Drug discovery, Idiopathic pulmonary fibrosis, Drug design, Fibrosis, Enzyme, Doctor of Philosophy, IPF, Pharmaceutical industry, TG2

NEW YORK, Jan. 12, 2023 /PRNewswire/ -- Cambrian BioPharma, a multi-asset longevity biotech, today unveils its latest pipeline company, Isterian Biotech. This preclinical start-up is working towards the development of first-in-class small molecule inhibitors of transglutaminase 2 (TG2), one of the major crosslinking enzymes in the human body, which becomes more active during aging resulting in fibrotic diseases.

Key Points: 
  • NEW YORK, Jan. 12, 2023 /PRNewswire/ -- Cambrian BioPharma , a multi-asset longevity biotech, today unveils its latest pipeline company, Isterian Biotech .
  • "Using this state-of-the-art approach to drug discovery combined with an impressive team gives us great confidence in the future of this novel company."
  • In 2019, Aston University partnered with Cambrian to form Isterian Biotech with a mission to develop safe and effective TG2 inhibitors to treat Idiopathic pulmonary fibrosis (IPF), a devastating fibrotic disease of the lung.
  • "Isterian and its work to reduce fibrosis are a perfect fit alongside the other pipeline companies our team has announced in 2022."

Antelope Enterprise Appoints New Board Directors

Retrieved on: 
Thursday, November 3, 2022
Aston, Board, Security (finance), Nomination, IPO, Ownership, U.S. Securities and Exchange Commission, Form 20-F, SEC, Forward-looking statement, Social commerce, Software, Management accounting, National university, Securities Act of 1933, CEO, Marketing, Master, Annual report, Special-purpose acquisition company, Software as a service, General manager, Eaton Square, Company, Islamic banking and finance, Australian National University, Electronic engineering, Platform as a service, Aston University, Board of directors, Investment, Goal, Financial management, Compensation, Bachelor, Audit, Nasdaq, Securities Exchange Act of 1934, Monash University, Management, PRC

JINJIANG, China, Nov. 3, 2022 /PRNewswire/ -- Antelope Enterprise Holdings Limited (NASDAQ Capital Market: AEHL) ("Antelope Enterprise" or the "Company"), which engages in business management, information systems consulting, and online social commerce and live streaming, and is a manufacturer of ceramic tiles used for exterior siding and for interior flooring and design in residential and commercial buildings in China, today announced that effective November 3, 2022, its Board of Directors has appointed Mr. Qiguo Wang and Mr. Dian Zhang as members of the Company's Board of Directors.

Key Points: 
  • JINJIANG, China, Nov. 3, 2022 /PRNewswire/ -- Antelope Enterprise Holdings Limited (NASDAQ Capital Market: AEHL) ("Antelope Enterprise" or the "Company"), which engages in business management, information systems consulting, and online social commerce and live streaming, and is a manufacturer of ceramic tiles used for exterior siding and for interior flooring and design in residential and commercial buildings in China, today announced that effective November 3, 2022, its Board of Directors has appointed Mr. Qiguo Wang and Mr. Dian Zhang as members of the Company's Board of Directors.
  • The Board of Directors now comprises seven directors, which is an increase from its previous five members, and which includes four independent directors.
  • "We welcome Messrs. Wang and Zhang to our Board and are confident that they will make positive contributions to the Company based on their experience and backgrounds," said Ms. Meishaung Huang, CEO of Antelope Enterprise.
  • Antelope Enterprise Holdings Limited engages in business management, information systems consulting, SaaS (software as a service) and PaaS (platform as a service) systems platforms,and online social commerce and live streaming in China.

Evox Therapeutics Appoints Peter Jones as Vice President of CMC

Retrieved on: 
Thursday, April 14, 2022
Aston, Process, Engineering, Hertfordshire, Chemical engineering, GlaxoSmithKline, Orchard, Biology, Royal Academy of Arts, Royal Academy of Engineering, Oxford BioMedica, Master of Science, API, Central nervous system, Brain, GLOBE, Biochemical engineering, Patient, Cell, Tissue, Institution of Chemical Engineers, Technology, Lego Star Wars: The Complete Saga, CAR, CD19, University of Hertfordshire, CMC, University college, Bachelor of Science, Exosome, Oxford, Antibody, University, Aston University, Health, Seminal vesicles, Therapy, Pharmaceutical industry, Fine chemical, Genzyme, Discovery

OXFORD, United Kingdom, April 14, 2022 (GLOBE NEWSWIRE) -- Evox Therapeutics Ltd (Evox or the Company), a leading exosome therapeutics company, announces the appointment of Peter Jones as Vice President of CMC.

Key Points: 
  • OXFORD, United Kingdom, April 14, 2022 (GLOBE NEWSWIRE) -- Evox Therapeutics Ltd (Evox or the Company), a leading exosome therapeutics company, announces the appointment of Peter Jones as Vice President of CMC.
  • Mr. Jones has more than 30 years of process development experience in the biopharmaceutical industry, building and leading cross-functional teams to support clinical and commercial development.
  • Before joining Evox, he was Executive Director, Process Development at Autolus Therapeutics plc, where he led late-stage CMC activities for the AUTO1 (obe-cel) CD19 CAR T cell therapy program.
  • Evox Therapeutics is a privately held, Oxford-based biotechnology company focused on harnessing and engineering the natural delivery capabilities of extracellular vesicles, known as exosomes, to develop an entirely new class of therapeutics.

Bill Boas is recognized by Continental Who's Who

Retrieved on: 
Friday, March 11, 2022
Aston, Computer-mediated communication, Computer scientist, Clifton College, University, Shareholder, Business, Aston University, VP, General Electric LM2500, School, Computer, Distinguishing, Research, Business development, Engineering, Communication, Royal Navy, John Bates (technology executive), Multimedia, Lawrence Livermore National Laboratory, Continental, Bachelor of Science, Essential, Ultra Network Technologies, National Coastal Zone Management Program, Technology, Wi-Fi, Program, IEEE Life Sciences, EMS, Software, Kellogg-HKUST Executive MBA Program, Center, Mechanics, Infrastructure, University of California, McGill University, OpenFabrics Alliance, CEO, Founder, Mobile phone, Physics, Chemistry, Industry

ABIQUIU, N.M., March 11, 2022 /PRNewswire/ --Bill Boas is being recognized by Continental Who's Who as a Distinguished Lifetime Achiever in the Communications Infrastructure field and in acknowledgment of his work at Essential Community Communications Infrastructure.

Key Points: 
  • ABIQUIU, N.M., March 11, 2022 /PRNewswire/ --Bill Boas is being recognized by Continental Who's Who as a Distinguished Lifetime Achiever in the Communications Infrastructure field and in acknowledgment of his work at Essential Community Communications Infrastructure.
  • Bill Boas developed expertise in supercomputers, broadband, 5G, and Wifi networks for enterprise sites and community sites throughout his 25 years as a Technology Executive.
  • At his first job, Mr. Boas was the Regional Sales Manager at Ultra Network Technologies from 1987-1992.
  • Today, Mr. Boas is the Founder and CEO of Essential Community Communications Infrastructure LLC, based in Abiquiu, New Mexico.